U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07136428) titled 'Asciminib in HER2+ Breast Cancer Brain Metastases' on Aug. 15.
Brief Summary: The purpose of this study is to evaluate the intracranial response rate of a combination of asciminib/trastuzumab for the treatment of patients with metastatic HER2+ breast cancer with brain metastases.
Study Start Date: Nov. 01, 2025
Study Type: INTERVENTIONAL
Condition:
HER2+ Metastatic Breast Cancer
Intervention:
COMBINATION_PRODUCT: Asciminib and Trastuzumab
Each study treatment cycle will last 21 days. Asciminib will be taken orally every day during the treatment period at the dose determined as the MTD during the safety lead-in in combination ...